

ID Number	Group	Gender	Age	Cutaneous signs	Respiratory signs	Cardiovascular signs	Severity grade	cysLT µg/L	Histamine nmol/L	Tryptase µg/L	IgE (%)	IDT
1	A	M	80	erythema	bronchospasm	shock	3	93.1	12820	377	19.5	pos
2	A	F	25	erythema	bronchospasm	shock	3	59.6		47.8	7.4	pos
3	A	F	75	erythema	bronchospasm	shock	3	52.7	782	258	16.4	pos
4	A	M	82	erythema	bronchospasm	shock	3	44.2	844	51.6	10.8	pos
5	A	M	50	erythema		shock	3	37	277	34.5	4.4	pos
6	A	F	67	erythema	bronchospasm	cardiac arrest	4	36	7160	313	1.9	pos
7	A	M	48		desaturation	cardiac arrest	4	29.4	95.5	629	12.1	pos
8	A	M	37	erythema	bronchospasm	shock	3	26.7	1323	7.1	7.1	pos
9	A	F	51	erythema	bronchospasm	shock	3	24.7	757	36	17.2	pos
10	A	M	52	erythema	bronchospasm	shock	3	21.1	20.5	12	10.9	pos
11	A	F	47	delayed erythema, face and mucosal oedema		cardiac arrest	4	19.6	7265	419	20.6	pos
12	A	M	46	erythema	bronchospasm	shock	3	18.7	1071	322	16.5	pos

13	A	M	52	erythema		shock	3	17.9	467	19.5	9.9	pos
14	A	F	52	erythema	bronchospasm	shock	3	17.8	232	60.5	6.2	pos
15	A	M	55	erythema		hypotension	2	16.2	33.9	21.9	3.4	pos
16	A	F	33	erythema	bronchospasm	shock	3	16.1	82.4	215	2.5	pos
17	A	M	83	erythema		cardiac arrest	4	8.3	1860	78	2.7	pos
18	A	M	67	erythema	bronchospasm	shock	3	7.9	36.8	174	19.6	pos
19	A	F	30	erythema	bronchospasm	shock	3	7.8	16.8	41.6	16.1	pos
20	A	F	52	erythema		cardiac arrest	4	7.3	90.2	51.3	2.8	pos
21	A	F	59	erythema		tachycardia	2	3.9	140	19.3	6.1	pos
22	A	M	28	erythema	hypocapnia	shock	3	2.4	2820	327	6.0	pos
23	A	M	36			shock	3	2.3	183	167	0.29	pos
24	A	F	68	erythema	bronchospasm	shock	3	1.0	64	7.9	25.6	pos
25	B	F	59	urticaria			1	14.2	9.3	10.4	2.9	neg
26	B	F	41	urticaria		tachycardia	2	11.7	4.2	3.3	0.98	neg
27	B	F	53	erythema		hypotension	2	11.5	2.3	3.6	0.68	neg
28	B	F	49	erythema, diffuse oedema			1	11.5	3.0	4.3	1.6	neg
29	B	F	25	erythema	bronchospasm	tachycardia	3	11.4	2.9	3.9	1.8	neg

30	B	F	60	erythema		hypotension	2	3.2	3.0	8.8	0.6	neg
31	B	M	78			cardiac arrest	4	3.2	2.5	4.3	1.5	neg
32	B	M	73	erythema		shock	3	3.0	5.0	4.7	1.6	neg
33	B	F	58	urticaria		shock	3	0.83	7.5	5.6	0.4	neg
34	B	F	58	erythema, urticaria, lips oedema			1	0.49	5.0	2.6	0.45	neg
35	C	F	62					1.73				
36	C	M	59					1.59				
37	C	F	60					1.58				
38	C	F	77					1.57				
39	C	M	44					1.53				
40	C	M	64					1.42				
41	C	M	56					1.41				
42	C	F	86					1.02				
43	C	F	60					0.94				
44	C	M	48					0.83				
45	C	F	63					0.79				
46	C	F	64					0.76				

47	C	F	62					0.72				
48	C	F	28					0.65				
49	C	F	65					0.65				
50	C	F	81					0.64				
51	C	F	53					0.63				
52	C	M	82					0.62				
53	C	M	69					0.60				
54	C	M	63					0.56				
55	C	M	51					0.54				

Supplementary Table 1 : Individual description of the patients, indicating clinical signs and severity grade of the reaction (if appropriate) according to the Ring and Messmer scale (18), and concentrations of cysteinyl leukotriene C4 D4 E4 (cysLT) at 30 min-1 h after reaction (or <30 min if not available) ; plasma histamine <30 min after reaction (or at 30 min-1 h if missing); tryptase at 30 min-1 h (or 2 h-6 h if missing); IgE against neuromuscular blocking agents and results of allergy intradermal tests (IDT). Group A: allergic hypersensitivity reactions; Group B: non-allergic hypersensitivity reactions; Group C: controls. Histamine was not detectable in patient 2 (pregnant woman).

Normal values: histamine : < 6 nmol/L; tryptase: < 12.5 µg/L; IgE: < 2 %.

Neg: negative; pos: positive; M: male; F: female.